Stockreport

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer cohort data readout in first half [Read more]